Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis (PRIME)

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Avanir Pharmaceuticals

ClinicalTrials.gov Identifier:

NCT01324232

First received: March 23, 2011

Last updated: April 15, 2014

Last verified: April 2014

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	September 2013
Primary Completion Date:	September 2013 (Final data collection date for primary outcome measure)